CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...